Leading pharmaceutical and biotech companies, including Immunovant Sciences, Novartis Pharmaceuticals, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharmaceuticals, and ValenzaBio, are advancing their key drug candidates through various stages of clinical development. Among the promising new therapies are VRDN-001 from Viridian Therapeutics and IMVT-1401 from Immunovant Sciences GmbH, both expected to enter the market soon.
DelveInsight’s “Graves’ Ophthalmopathy Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Graves’ Ophthalmopathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Graves’ Ophthalmopathy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Graves’ Ophthalmopathy Overview
Graves’ Ophthalmopathy, also known as Thyroid Eye Disease (TED), is a complex and potentially debilitating orbital inflammatory condition primarily associated with thyroid dysfunction. Named after the Irish physician Robert J. Graves, who first described its association with thyrotoxicosis, this disease affects the muscles, eyelids, tear glands, and fatty tissues behind the eyes, leading to a range of ocular symptoms.
Key Features:
- Inflammation and Swelling: The condition causes inflammation in the tissues surrounding the eyes, which can result in symptoms such as red, swollen, and uncomfortable eyes. It may also lead to bulging or protrusion of the eyes (exophthalmos).
- Thyroid Dysfunction: Graves’ Ophthalmopathy often occurs in conjunction with untreated or poorly managed thyroid disorders, such as hyperthyroidism or hypothyroidism. Thyroid dysfunction is a significant factor in the development and progression of the disease.
- Risk Factors: Smoking is a major risk factor for the development of Graves’ Ophthalmopathy. Other potential contributing factors include genetic predisposition and environmental triggers.
Epidemiology:
- Prevalence: The prevalence of Graves’ Ophthalmopathy is estimated to be approximately 16 cases per 100,000 women and 2.9 cases per 100,000 men in the general population.
- Demographics: The condition predominantly affects females, with about 80% of cases occurring in women. The disease is also more common in individuals over the age of 30.
Symptoms and Complications:
- Ocular Symptoms: Patients may experience bulging eyes, double vision, eye pain, and difficulty closing the eyes. The severity of symptoms can range from mild to severe and can significantly impact a patient’s quality of life.
- Complications: Without treatment, Graves’ Ophthalmopathy can lead to serious complications such as vision impairment or loss, severe eye discomfort, and significant cosmetic changes.
Diagnosis and Treatment:
- Diagnosis: Diagnosis typically involves a combination of clinical evaluation, patient history, and imaging studies such as CT or MRI scans to assess the extent of orbital inflammation.
- Treatment: Management of Graves’ Ophthalmopathy often involves addressing the underlying thyroid disorder with antithyroid medications or surgery. Treatment options for the ophthalmopathy itself may include corticosteroids, orbital radiation therapy, or surgical interventions to alleviate symptoms and prevent further complications.
Market Outlook:
- Therapeutics Market: The Graves’ Ophthalmopathy therapeutics market is expected to see substantial growth due to increasing patient awareness, favorable reimbursement policies, and the introduction of new therapies. Major pharmaceutical and biotech companies are actively developing new treatment options, aiming to improve patient outcomes and manage the disease more effectively.
Research and Development:
- Emerging Therapies: Companies such as Novartis, Immunovant Sciences, and Viridian Therapeutics are leading the development of novel therapies for Graves’ Ophthalmopathy. Promising candidates in the pipeline, such as VRDN-001 and IMVT-1401, are anticipated to make a significant impact on the market and provide new treatment options for patients.
Graves’ Ophthalmopathy remains a critical area of research and development, with ongoing efforts to better understand the disease, improve treatment options, and ultimately enhance the quality of life for those affected.
According to NORD, the precise prevalence of Graves’ ophthalmopathy—defined as the number of individuals affected by the disorder within a specific population at a given time—is not definitively known. However, estimates suggest that it occurs in approximately 16 per 100,000 women and 2.9 per 100,000 men in the general population.
Graves’ Ophthalmopathy Market Key Facts
-
In 2023, the total Graves’ Ophthalmopathy market size was around USD 2,600 million, which is expected to increase by 2034 during the study period (2020–2034) in the 7MM.
-
Graves’ ophthalmopathy, also known as thyroid-associated ophthalmopathy and thyroid eye disease, is the most frequent extrathyroidal manifestation of Graves’ disease.
-
With estimated 1 million patients affected in the US, thyroid eye disease is a burben some disorder which become sight threatning in upto 5% of the cases
-
Thyroid-associated Ophthalmopathy remains largely undiagnosed due to less awareness among the treating physicians and asymptomatic nature of the disease
-
US has the highest prevalent cases of graves ophthalmopathy among the 7MM. Among the EU4 and the UK, out of all prevalent cases, Germany accounted for the highest number of cases followed by France and Spain accounted for the lowest number of cases in 2023.
-
Graves’ Ophthalmopathy management varies based on symptoms and severity, involving basic, medical, and surgical approaches. Corticosteroid therapy for 3 months may prevent or alleviate ophthalmopathy after radioactive iodine therapy. Botulinum toxin can temporarily treat dysthyroid strabismus during the acute phase.
-
Untill recently, the drug treatment was largely available only for patients in acute phase of the disease and surgery was the only option for the management of chronic disease form
-
Amgen’s TEPEZZA (trepotumab), one of the most successful launch for a rare indication, generated a revenue of ~USD 2 Billion in 2023 after becoming the first launched therapy for thyroid eye disease in the year 2020
-
The US FDA has granted clearance to Tourmaline Bio’s investigational new drug (IND) application enabling the initiation of a Phase IIb trial of TOUR006 to treat thyroid eye disease (TED). According to Tourmaline Bio, TOUR006 attributes demonstrated that it is long-acting with a terminal half-life of ~7 weeks and shows high affinity to IL-6.
-
In March 2024, ACELYRIN announced positive Phase I/II proof-of-concept data for lonigutamab, the first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease.
-
Key Graves Ophthalmopathy Companies such as Immunovant Sciences and Viridian Therapeutics are expected to transform the treatment landscape for Graves’ Ophthalmopathy patients.
-
As potential treatments for chronic Graves’ Ophthalmopathy develop, understanding its clinical presentation and impact on QoL grows crucial. Further exploration, particularly through prospective studies integrating patient-reported outcomes and clinical examinations, is warranted. Concurrently, the unique dynamics of the TED market offer a promising opportunity for innovative therapeutic strategies.
Approximately 50% of individuals with Graves’ Disease experience symptoms of Graves’ Ophthalmopathy, which are often mild.
Diagnosis of Graves’ Ophthalmopathy is usually based on a clinical assessment of ocular symptoms and signs. Early diagnosis is crucial as it allows for proper evaluation and treatment, potentially preventing the development of more severe manifestations. The most prevalent signs of Graves’ Ophthalmopathy are upper eyelid retraction, seen in about 90% of patients, and proptosis (bulging of the eyes).
Graves’ Ophthalmopathy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
Graves’ Ophthalmopathy Treatment Market
Graves’ ophthalmopathy is an autoimmune inflammatory disorder linked with thyroid disease, affecting ocular and orbital tissues. It is also referred to as Graves’ orbitopathy, Graves’ eye disease, thyroid eye disease (TED), or thyroid-associated ophthalmopathy.
This condition is the primary extrathyroidal manifestation of Graves’ disease (GD) and can be severely disfiguring, significantly impacting the quality of life (QoL) of those affected while imposing substantial direct and indirect costs on healthcare systems.
Graves’ Ophthalmopathy presents a broad range of ocular symptoms, including irritation, conjunctival injection, periorbital swelling, exposure keratopathy, lid retraction, exophthalmos (bulging eyes), diplopia (double vision), and optic neuropathy. These symptoms result from inflammation and enlargement of the extraocular muscles (EOMs) and fat compartments within the orbit.
Diagnostic imaging, such as computed tomography (CT) or magnetic resonance imaging (MRI), is utilized to assess the enlargement of the EOMs and fat compartments.
Learn How the Graves’ Ophthalmopathy Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/sample-request/graves-ophthalmopathy-market
Leading Companies in the Graves Ophthalmopathy Therapeutics Market Include:
-
Novartis
-
Harbour BioMed
-
Viridian Therapeutics, Inc.
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
-
Sling Therapeutics, Inc.
-
ValenzaBio
-
Argenx
-
HanAll Biopharma
-
Immunovant Sciences
-
Novartis
-
Viridian Therapeutics
Graves Ophthalmopathy Therapies Covered in the Report Include:
-
Tepezza (teprotumumab) : Horizon Therapeutics
-
Secukinumab: Novartis
-
Batoclimab (HBM9161): Harbour BioMed
-
TEPEZZA (teprotumumab): Horizon Therapeutics
-
Batoclimab: Immunovant Sciences
-
VRDN-001: Viridian Therapeutics
-
Linsitinib : Sling Therapeutics
Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/graves-ophthalmopathy-market
Table of Contents
1. Key Insights
2. Executive Summary
3. Graves’ Ophthalmopathy Competitive Intelligence Analysis
4. Graves’ Ophthalmopathy Market Overview at a Glance
5. Graves’ Ophthalmopathy Disease Background and Overview
6. Graves’ Ophthalmopathy Patient Journey
7. Graves’ Ophthalmopathy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Graves’ Ophthalmopathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Graves’ Ophthalmopathy Unmet Needs
10. Key Endpoints of Graves’ Ophthalmopathy Treatment
11. Graves’ Ophthalmopathy Marketed Products
12. Graves’ Ophthalmopathy Emerging Drugs and Latest Therapeutic Advances
13. Graves’ Ophthalmopathy Seven Major Market Analysis
14. Attribute Analysis
15. Graves’ Ophthalmopathy Market Outlook (In US, EU5, and Japan)
16. Graves’ Ophthalmopathy Access and Reimbursement Overview
17. KOL Views on the Graves’ Ophthalmopathy Market
18. Graves’ Ophthalmopathy Market Drivers
19. Graves’ Ophthalmopathy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
